Oxford University Innovation

What Oxford University Innovation does

Oxford University Innovation (OUI) is a private limited company and wholly-owned subsidiary of the University of Oxford that has served as the university's technology transfer and innovation commercialization arm since 1987. The organization identifies, protects, and commercializes intellectual property generated by Oxford researchers across the university's four academic divisions, providing services spanning IP protection, licensing, spinout company formation, and consulting facilitation. In FY 2024/25, OUI recorded 279 invention disclosures and 961 consulting enquiries, with activities generating £18.5 million in royalty and consulting income distributed to the University, researchers, and contractual rights holders. The company employs 51–100 staff at its Oxford headquarters at Buxton Court and operates as the sole gateway between Oxford research output and external commercial channels.

OUI operates the University Challenge Seed Fund (UCSF), the UK's longest continuously running proof-of-concept fund, which has invested £18.5 million across 316 projects over 25 years and is credited with supporting 97 spinouts (40% of Oxford's 248 total spinouts since 2000). UCSF-backed companies have collectively raised £2.97 billion in external funding, with seven reaching public-market listings. Revenue streams combine licensing royalties, equity stakes managed on behalf of the University in spinout companies, consulting service facilitation connecting clients to more than 6,500 Oxford experts from over 50 departments, and tiered subscription income from the Oxford Innovation Society membership programme (£1,500 to £10,500 per year across SME, Corporate, and Large Corporate tiers).

Notable commercial outcomes include the October 2025 acquisition of OrganOx by Terumo Corporation for $1.5 billion (the largest Oxford spinout exit on record), the acquisition of Oxford Ionics by IonQ for $1.075 billion, and Samsung Electronics's acquisition of Oxford Semantic Technologies. OUI has facilitated more than 350 company creations since 1987 and manages a portfolio of over 2,200 patents filed since 2000. The organization also licenses validated clinical outcome assessments (BVAS, VDI, Steroid PRO, AAV-PRO, GCA-PRO) and runs translational funding programmes including the University Challenge Seed Fund. Leadership comprises Dr Mairi Gibbs as permanent CEO (from June 2024) and Jaci Barnett as COO (from September 2024), under the chairmanship of Baroness Nicola Blackwood.

Name

Oxford University Innovation

Legal name

Oxford University Innovation Limited

Website

https://innovation.ox.ac.uk

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

51–100 employees

Short description

Oxford University Innovation (OUI) is the wholly-owned technology transfer subsidiary of the University of Oxford, commercializing Oxford research through IP licensing, spinout formation, and consulting services across life sciences, quantum computing, AI, and clean technology since 1987.

Ownership category

akta.pro rank

Product category

Technology Transfer Services

NAICS

Colleges, Universities, and Professional Schools (61131), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Patent Owners & Lessors (6794), Services-Management Consulting Services (8742), Investment Advice (6282)

akta.pro primary industry

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

akta.pro secondary industries

STEM-Focused Research Universities (Engineering & Applied Sciences) (EDAHABAB), Technical Universities with Entrepreneurship & Incubation Focus (EDAHAEAH)

Keywords

• Technology transfer services
• University spinout formation
• Intellectual property licensing
• Academic consulting services
• Proof-of-concept funding

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Licensing Revenue: Royalty and licensing income from technologies licensed to industry partners, with distributions to University, researchers and third parties with contractual revenue sharing rights
2. Equity Stakes in Spinouts: Financial returns generated through company creation, with OUI managing University's equity stakes in spinouts; revenue shared with researchers and departments
3. Consulting Services: Facilitation of Oxford expert consultants to external organizations, providing access to over 6,500 experts from more than 50 departments
4. Oxford Innovation Society Membership: Annual membership fees from three tiers: SME (£1,500+ VAT), Corporate (£8,000+ VAT), Large Corporate (£10,500+ VAT)

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Oxford University Innovation is the technology transfer and innovation partner of the University of Oxford, providing services across IP identification and protection, spinout company creation and growth, technology licensing, and academic consultancy facilitation. The organization connects Oxford's 6,500+ researchers with industry partners, investors, and external organizations seeking access to Oxford innovations and expertise. Revenue is generated through licensing royalties, equity stakes in spinout companies, consultancy fees, and membership subscriptions.

Product overview

Oxford University Innovation (OUI) is the technology transfer organization for the University of Oxford, offering a portfolio of licensing opportunities, clinical outcome assessments, proof-of-concept funding, and innovation ecosystem services. OUI's Clinical Outcomes team manages a suite of validated patient-reported outcome measures (COAs) including Steroid PRO, AAV-PRO, GCA-PRO, BVAS, VDI, and Mini-OCS, available for licensing. The organization also facilitates licensing of Oxford research technologies including the Universal HLA-E mRNA vaccine platform, HPV immunotherapy platform, and TCR therapies. OUI operates the University Challenge Seed Fund (UCSF), provides membership through the Oxford Innovation Society, and supports spinout companies including OrganOx metra for liver transplantation.

Differentiator

Problem solved

Functional benefit

Brands

• Oxford Innovation Society (OIS): A collaborative forum managed and facilitated by OUI where Oxford researchers, founders, investors, and industry partners connect to share ideas, build relationships, and explore new opportunities.
• University Challenge Seed Fund (UCSF)

Products and services

• Steroid PRO The first validated and reliable patient-reported outcome measure (PRO) designed specifically to evaluate the well-being of patients undergoing glucocorticoid therapy for rheumatic diseases. A 15-item scale with 4 domains: social impact, impact on appearance, psychological impact, and treatment concerns. Available for licensing.
• AAV-PRO (ANCA-associated vasculitis PRO) A disease-specific patient-reported outcome measure for ANCA-associated vasculitis, used to assess health-related quality of life and disease burden experienced by patients. Available for licensing.
• GCA-PRO (Giant Cell Arteritis PRO) A validated outcome measure for use in clinical trials, observation studies and clinical practice to measure symptoms and impact on health-related quality of life in patients with Giant Cell Arteritis. Available for licensing.
• BVAS (Birmingham Vasculitis Activity Score) The gold-standard tool for assessing vasculitis disease activity across various organ systems, providing reliable measures for use in clinical trials and studies, helping predict long-term outcomes like relapse and mortality. Available for licensing.
• VDI (Vasculitis Damage Index) An evaluation tool that measures irreversible damage caused by vasculitis or its treatments, offering insights into long-term patient prognosis and quality of life. Available for licensing.
• Mini-Oxford Cognitive Screen (Mini-OCS) A rapid, stroke-specific cognitive screening tool for primary and community care, providing a sensitive 7-9 minute assessment of cognitive function. Available for licensing.
• Statin Side Effects Risk Calculator A calculator developed by University of Oxford researchers that estimates individual risk of serious muscle disorders from statins, based on data from 5.6 million people. Available for licensing.
• Universal HLA-E mRNA Vaccine Platform Technology utilizing mRNA-encoded HLA-E-beta2 microglobulin-peptide single-chain trimers to directly present target antigens on cell surfaces, enabling robust HLA-E presentation. Available for licensing.
• Universal HLA-E Targeted HPV Immunotherapy Platform Technology comprising antibodies, TCRs, and CAR-T cells targeting HPV-derived peptides presented by the non-polymorphic HLA-E molecule for universal immunotherapy applications. Available for licensing.
• HLA-E Enabled Universal Wilm's Tumour-1 TCR Therapy Patented technology covering T cell receptors (TCRs) specific for a WT1 peptide presented by HLA-E, alongside nucleic acids and associated components. Available for licensing.
• University Challenge Seed Fund (UCSF) The UK's longest continuously running proof-of-concept fund supporting early-stage projects with market potential, investing between £2,500 and £250,000. Managed by OUI for Oxford University researchers with quarterly calls.
• Oxford Innovation Society A collaborative forum connecting Oxford researchers, founders, investors, and industry partners. Membership options include SME (£1,500/year), Corporate (£8,000/year), and Large Corporate (£10,500/year).
• EIT Pathogena A genomic analysis tool launched by the Ellison Institute of Technology for detecting and analyzing Mycobacterium tuberculosis and other pathogens. Built on Oracle cloud technology.

Quantifiable outcome

• 97 spinouts created with UCSF support, representing 40% of Oxford's total 248 spinouts since 2000
• +4 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• University of OxfordcoreStrategic or Co-development Partner · 1 January 2000OUI works as the innovation partner of the University of Oxford, using commercial expertise to turn academic knowledge and research into real-world applications
• TenUmajorStrategic or Co-development PartnerInternational collaboration of ten technology transfer offices (TTOs) of world-leading universities; OUI holds presidency for 2026
• Koa HealthmajorOEM/ Whitelabel/ Licensing PartnerCommercial licence partnership for four online mental health therapies (anxiety, PTSD) developed by Oxford experts, now available across NHS Trusts
• Ellison Institute of TechnologymajorStrategic or Co-development PartnerMultidisciplinary research and innovation organization developing scalable solutions to global challenges through partnership with University of Oxford
• Apollo TherapeuticsmajorStrategic or Co-development PartnerDrug discovery and development collaboration with University of Oxford, bringing capital and therapeutic development expertise to Oxford researchers
• LSE InnovationminorStrategic or Co-development PartnerCo-leading training and knowledge dissemination for Impact U (formerly Impact 12) social venture consortium with OUI
• Cambridge EnterpriseminorStrategic or Co-development PartnerPart of Impact U consortium for university social ventures, collaborating on Pathfinder Awards and knowledge-sharing ecosystem
• NIHR Oxford Biomedical Research CentreminorStrategic or Co-development PartnerProvided early support for OrganOx clinical development

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cambridge Enterprise: University of Cambridge's technology transfer office, the closest UK peer to OUI. Operates the same mix of spinout creation, licensing, and proof-of-concept funding (Cambridge Enterprise Seed Funds) at a similarly prestigious research university.
• MIT Technology Licensing Office: MIT's TTO handling invention disclosures, patenting, and licensing for one of the world's highest-volume commercialization universities. Comparable model and global licensing footprint to OUI's, with comparable depth in STEM research.
• Stanford Office of Technology Licensing: Stanford's TTO is widely regarded as the high-water mark for university spinout creation, including Google and biotech origins. Direct global peer to OUI given its emphasis on equity retention and high-value exits.
• UCL Business: UCL's commercialization arm operating UCLB, delivering spinout creation, licensing and consultancy at a major UK research university. Closely comparable business model and customer base (researchers, licensees, investors) to OUI.
• Imperial College Innovations: Imperial College London's TTO focused on STEM spinouts in deep tech and health. Direct UK peer to OUI with a comparable mix of licensing, equity stakes and seed funding through the Imperial College Innovation Fund.
• Columbia Technology Ventures: Columbia University's TTO managing IP licensing and spinout formation, including startups from Columbia's engineering, medical, and data science faculties. Comparable scale and operating model to OUI.

Broad incumbents

• IP Group plc: Publicly listed UK firm specializing in commercializing university-derived IP via long-term equity investments and spinout creation. Competes with OUI for the same UK university deal flow, but operates as an investment firm rather than an in-house TTO.

Others

• Oxford Science Enterprises: Dedicated investment company backing Oxford spinouts, partnered with OUI through UCSF (including a £3m top-up in 2018). Ecosystem participant rather than direct competitor - co-creates and co-funds the spinouts OUI originates.
• Apollo Therapeutics: Drug discovery and development collaboration between Oxford, Cambridge, Imperial, UCL and three global pharma companies. Strategic partner rather than competitor - adds downstream therapeutic development capability to OUI-licensed academic research.
• TenU: International consortium of ten leading university TTOs (including OUI) collaborating on best-practice, training and shared services. Ecosystem participant rather than a competitor; OUI holds the consortium presidency for 2026.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@oxforduniversityinnovation5680
• LinkedInlinkedin.com/company/oxford-university-innovation
• Xx.com/OxUInnovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments65 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford University Innovation